Product
AT2221
Aliases
Miglustat
Name
Zavesca
INN Name
Miglustat
FDA Approved
Yes
4 clinical trials
5 organizations
1 indication
4 documents
Indication
Pompe DiseaseClinical trial
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Expanded Use Of Recombinant Human Acid Alpha-Glucosidase/N-butyl-deoxynojirimycin (ATB200/AT2221) For Patients With Infantile-Onset Pompe DiseaseStatus:
Clinical trial
Named Patient or Compassionate Use for Treatment Use of ATB200/AT2221 for Patients With Pompe DiseaseStatus:
Document
DailyMed Label: ZavescaOrganization
Actelion Pharmaceuticals US, Inc.Document
DailyMed Label: MiglustatOrganization
CoTherix, Inc.Organization
ANI Pharmaceuticals, Inc.Document
DailyMed Label: OPFOLDAOrganization
Amicus Therapeutics US, LLCDocument
DailyMed Label: YargesaOrganization
Edenbridge Pharmaceuticals LLC.